argenx SE is a biopharmaceutical company developing therapies for autoimmune and related disorders, with operations across the United States, Japan, China, and Europe. The company markets VYVGART and VYVGART HYTRULO for conditions including generalized myasthenia gravis, immune thrombocytopenia, and related inflammatory neuropathies, while maintaining a pipeline of investigational antibody-based treatments targeting various immune and inflammatory pathways. The company collaborates with multiple partners on drug development and commercialization efforts.
1Y: 995.77 (+36.1%) · range 663.93–1,058.90
entry readiness 10 · NOT READY · exit proximity 0
Value area 774.87–919.99 · 12% of 120d volume overhead · clean runway
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +16.88% | +19.21% | mature |
| 40d | +12.86% | +21.40% | 32/40d |